Biogen Idec Gearing Up For Major LaunchesSeeking AlphaBiogen also benefits from the fact that two of its potential competitors – daclizumab and ocrelizumab – are partnered programs with Abbott (ABT) and Roche (RHHBY.PK), respectively, and Biogen contro…
NMSS reports clinical trial alert in Bradenton, FL and other cities nationwideExaminer.comThe National Multiple Sclerosis Society (NMSS) announced a trial alert yesterday for the study of daclizumab high yield process (DAC HYP). The alert stated the st…
Chicago TribuneAbbott christens new pharma company AbbViePMLiVE… gonadotropin-releasing hormone (GnRH) antagonist elagolix, partnered with Neurocrine Biosciences and in testing for endometriosis, as well as bardoxolone for chronic kidney disease, can…
Multiple Sclerosis Therapeutics – Pipeline Assessment and Market Forecasts to 2019SBWire (press release)Aubagio (teriflunamide), Dimethyl Fumarate (BG-12), Daclizumab, RG1594 (ocrelizumab) and Lamtrada (alemtuzumab) are the novel late stage pipeline pr…
Stem Cells Can Help in Kidney TransplantsMedPage TodaySince mesenchymal stem cells have been reported to be useful in treating graft-versus-host disease, they decided to see if the approach could be used to replace antibody induction with basiliximab (…
Biogen Inks Deal With MAKScientificDaily Markets (blog)Besides BG-12, Biogen is developing other multiple sclerosis candidates like daclizumab, in partnership with Abbott Labs (NYSE:ABT), and PEGylated interferon. Biogen has also been pretty active on …
Biogen Inks Deal with MAKScientific – Analyst BlogNASDAQBesides BG-12, Biogen is developing other multiple sclerosis candidates like daclizumab, in partnership with Abbott Labs ( ABT ), and PEGylated interferon. Biogen has also been pretty active on th…
Biogen Inks Deal with MAKScientificZacks.comBesides BG-12, Biogen is developing other multiple sclerosis candidates like daclizumab, in partnership with Abbott Labs (ABT), and PEGylated interferon. Biogen has also been pretty active on the deal-making/…
Biogen Idec Takes Option to MAKScientific MS ProgramGenetic Engineering NewsBiogen Idec's MS pipeline comprises Peg IFN, BG-12, and daclizumab, all of which are in Phase III for relapsing forms. Anti-Lingo is being investigated in Phase I. The comp…
Citybizlist (press release)Biogen Idec Chief George Scangos Among 25 Most Influential People in Biopharma …Citybizlist (press release)based company's "stock took off last year, fueled by positive data on key experimental therapies such as th…